contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


intervacc-publicerar-arsredovisning-for-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

US approval will decide the fate of this stock. The product is good, but local trials still need to be executed correctly to obtain the approval. Additional expertise has been recruited to the management team and the board; let’s see how they perform. It will likely take a couple more years. At what stage and with what probability the market will start front-running the future remains to be seen.

The share price of this stock has picked up a bit; has there been anything noteworthy in the data or news? The rise started after the video was published; could that be the reason? My own Swedish skills aren’t sufficient to evaluate it.

Hello, a brand new interview with Intervacc’s new CEO Carl-Johan Dalsgaard about, among other things, the situation in the American market, challenges that must be overcome, and future prospects.

Its time will surely come. The product is very good in terms of its effectiveness; its need is just somewhat relative. Adoption takes its time. Sales are indeed slowly growing, but USA approvals are needed (as always in pharma) to truly make a profit. That will still take a couple of years. Recently, a new CMO was also hired, whose background is with the animal-side “big pharma” Idexx Laboratories. Here, I ended up leaving about +1000% gains on the table, as an optimistic holder, I didn’t know how to sell, but rather talked myself into believing that there were some grounds for the valuation (during zero-interest rate times).

It’s interesting that the commercialization project for the vaccine product continues, with more countries in the distribution scope, etc. In itself, the company’s stock price is at rock bottom, if not below the basement floor.                   Inderes              Intervacc and Dechra extend distribution agreement for Intervacc's equine...    Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will...

It is worth noting that the customer is conservative. The product is very good; the marketing work just needs to be done.  For those with a risk tolerance, there are good opportunities to buy the stock. Those with lower risk tolerance should wait for US marketing authorization; there could still be surprises and expenses from there.

Intervacc Q2: Net sales 1.9 M (SEK)  Operating loss -18 M  Net loss for the period -18 M To put it plainly, a total fiasco. International sales of the miracle vaccine are a ridiculous 160 thousand euros, which is on the same level as the turnover of some local car repair shop in Kajaani. Yet the company’s market value is still 26 M euros. I don’t understand…

Intervacc

Intervacc AB (publ) meddelar idag att bolagets årsredovisning för verksamhetsåret 2025 har publicerats. Årsredovisningen bifogas och finns även tillgänglig för nedladdning på företagets hemsida...

Intervacc AB (publ) meddelar idag att bolagets årsredovisning för verksamhetsåret 2025 har publicerats. Årsredovisningen bifogas och finns även tillgänglig för nedladdning på företagets hemsida <a href="http://intervacc.se/investerare/rapporter/">intervacc.se</a>.För mer information vänligen kontakta:Carl-Johan Dalsgaard, VD Tel: +46 (0)8 120 10 600E-post: carl-johan.dalsgaard@intervacc.se&nbsp;Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 14 april 2026, kl 08.30 CET.Om Intervacc Intervacc AB utvecklar och säljer vaccin mot djursjukdomar baserat på den egenutvecklade teknikplattformen med fusionerade rekombinanta proteiner. Bolagets vaccin och vaccinkandidater bygger på mångårig forskning vid Karolinska Institutet och Sveriges Lantbruksuniversitet. Intervacc aktien (Nasdaq: IVACC) är noterad på Nasdaq First North Growth Market. För ytterligare information se hemsidan intervacc.seKontaktuppgifter Certified AdviserEminova Fondkommission ABE-post: adviser@eminova.se, Tel: +46 (0)8 - 684 211 10<div></div>